Scaling Mature Field Reimbursement Programs with Confidence



Brandy Fidler
MODERATOR
Business Editor,
BioXconomy



Patrick Sadongo
Senior Manager, Field Reimbursement Services,
CoverMyMeds



Kim Howard
Senior Manager, Field Reimbursement Services,
CoverMyMeds

informa connect

covermymeds®


In this Q&A, CoverMyMeds experts follow-up with additional information, building upon their informative webinar of the same title.

How do field reimbursement program metrics compare across different therapeutic areas, and what benchmarks should manufacturers use to evaluate their program's performance against industry standards?

Comparing field reimbursement programs across therapeutic areas is rarely an apples-to-apples exercise. The realities of supporting a rare disease therapy are very different from supporting a high-volume primary care product. Access barriers, provider workflows and payer requirements can vary significantly, which makes context critical when evaluating performance. Rather than focusing on a single industry benchmark, manufacturers often benefit most from understanding trends within their therapeutic area and whether patient access is improving over time. Metrics such as time to therapy, prior authorization (PA) approval rates and patient persistence remain important, but their meaning depends on the environment in which they are measured.

What are the most common pitfalls manufacturers face when transitioning from an in-house to an outsourced FRM model?

The transition to an outsourced model is often less about transferring responsibilities and more about managing change effectively. Provider expectations, institutional knowledge and established workflows do not automatically shift with a new operating model. Organizations that approach the transition with a clear vision for accountability, communication and continuity are generally better positioned to maintain a consistent experience for providers while supporting patient access goals.



What impact will AI, machine learning, and automation have on the field reimbursement landscape, and how are companies positioning their FRM teams to adapt to these technological advancements?

AI and automation should be viewed as tools that can make FRMs more informed and more effective, not as replacements for the human side of the business. Field reimbursement is still a relationship-driven and people-first model. Providers need support from someone who understands their workflow and can translate complex access requirements into practical next steps.

Across more complex payer environments, AI in the future can help equip FRMs with better insights — identifying PA risk, surfacing documentation gaps, and prioritizing outreach. This improves how prepared the FRM is going into each interaction.

However, this only works when the insight is paired with strong judgment and execution. One of the common challenges is assuming that better data alone will drive better outcomes. The value of the FRM model continues to be the ability to apply that information in real-world provider conversations. Technology strengthens the model, but the human interaction is what drives impact.

What are the key regulatory and compliance considerations when deploying FRMs, particularly regarding interactions with healthcare providers and patient data handling under HIPAA?

Compliance is not a separate work stream, it's foundational to how field reimbursement programs operate. As patient support models continue to evolve, organizations must ensure provider engagement, data handling and access support activities remain aligned with regulatory expectations.

The strongest programs tend to view compliance as an enabler of consistency and trust, embedding it into training, oversight and day-to-day operations rather than treating it as a check-the-box exercise.

How can teams establish effective collaboration between FRMs, hub services, market access teams, and sales representatives to maintain alignment on patient support strategies?

Supporting patients through increasingly complex access journeys requires coordination across multiple teams. Field reimbursement, hub services, market access and commercial organizations each play distinct roles, but alignment across those functions is essential.

Organizations that create clear communication pathways and shared visibility into access challenges are often better equipped to identify emerging trends and respond quickly when barriers arise.

How are field reimbursement programs adapting to emerging payer strategies like value-based contracts, outcomes-based reimbursement, and digital PA platforms?

Across programs with increasing payer complexity, FRM teams are having to become more proactive. Digital PA platforms, tighter documentation requirements, and value-based arrangements all increase the need for speed, accuracy, and visibility.

The best programs are using FRMs to identify payer friction earlier, coach offices on clean submissions, and bring field insight back to internal and client partners. This requires consistent visibility into trends and clear ownership of how insights are communicated.

One of the common challenges is that programs remain reactive even when the data exists to be proactive. Strong client partnership allows those insights to influence broader program strategy. The value of the FRM model is not just supporting individual cases but helping organizations respond to access barriers at scale.

What PA touchpoints prevent patient abandonment, and how do FRMs customize their approach for individual patients?

The PA process is where many patients get stuck, so the key touchpoints are early identification of requirements, clean first-pass submission, timely follow-up, and denial support.

The value of the FRM model continues to be the ability to apply that information in real-world provider conversations. Technology strengthens the model, but the human interaction is what drives impact.

— Patrick Sadongo, Senior Manager, Field Reimbursement Services, CoverMyMeds

The framework for PA submissions can taught, but the bigger value comes when FRMs have visibility into patient-level PA information. That visibility allows teams to distinguish between routine cases and those requiring more involved support.

This only works when there is consistency in how cases are reviewed and escalated. One of the common challenges is treating all cases the same, which can lead to missed intervention opportunities. The value of the FRM model is applying the right level of support at the right time to prevent patient drop-off.

Given trends like the Inflation Reduction Act (IRA) implementation, biosimilar competition, and increasing payer reviews, how do you anticipate field reimbursement strategies will need to evolve over the next 3-5 years?

Over the next few years, FRM strategies will need to be more disciplined, scalable and data-driven. With evolving market dynamics such as IRA implementation, biosimilar adoption and payer changes, we'll continue to see an increase in medication access complexity.

As a result, programs that can operate efficiently while staying clearly within compliance boundaries and translating field insights into action.



Across larger and more complex programs, success will depend on consistent execution, role definition, and strong reporting frameworks. One of the common challenges is relying on activity as a proxy for value rather than demonstrating impact on access. The role continues to evolve from general support to a structured access capability that drives measurable outcomes. ■

VISIT US

One of the common challenges is that programs remain reactive even when the data exists to be proactive. Strong client partnership allows those insights to influence broader program strategy.

— Kim Howard Senior Manager, Field Reimbursement Services, CoverMyMeds